Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

ABSTRACT:

Background

We evaluated Aβ misfolding in combination with Aβ_42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD) in individuals with subjective cognitive decline (SCD).

Methods

Baseline plasma samples (n = 203) from SCD subjects in the SCIENCe project and Amsterdam Dementia Cohort (age 61 ± 9 years; 57% male, mean follow-up time 2.7 years) were analyzed using immuno-infrared-sensor technology. Within 6 years of follow-up, 22 (11%) individuals progressed to MCI or dementia due to AD. Sensor readout values > 1646 cm^- 1 reflected normal Aβ folding; readouts at ≤ 1646 cm^- 1 reflected low and at < 1644 cm^- 1 high misfolding. We used Cox proportion

SUBMITTER: Stockmann J 

PROVIDER: S-EPMC7761044 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature